Vonoprazan is non-inferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.

Vonoprazan-based therapy resulted in a satisfactory eradication rate and was well tolerated for Helicobacter pylori eradication. Vonoprazan is comparable to proton pump inhibitors in clarithromycin-based bismuth-containing quadruple therapy as a first-line treatment for Helicobacter pylori infection. This article is protected by copyright. All rights reserved.